

# VHL (C-13): sc-100232

## BACKGROUND

Individuals harboring germline mutations in the tumor suppressor gene von Hippel-Lindau (VHL) exhibit an increased susceptibility to a variety of tumors including renal carcinoma, hemangioblastoma of the central nervous system and pheochromocytoma. The Elongin (SIII) complex has been identified as the functional target of the VHL protein. Elongin (SIII) is a heterotrimer composed of a transcriptional active subunit designated Elongin A and two regulatory subunits designated Elongin B and Elongin C. VHL functions by binding to the Elongin B and C subunits, inhibiting the transcriptional efficacy of the Elongin (SIII) complex. Different isoforms of VHL have been observed, encoded by alternatively spliced transcript variants. The molecular weight of each isoform varies between species.

## REFERENCES

1. Seizinger, B.R., et al. 1988. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. *Nature* 332: 268-269.
2. Decker, H.J., et al. Loss of heterozygosity on 3p in a renal cell carcinoma in von Hippel-Lindau syndrome. 1989. *Cancer Genet Cytogenet.* 39: 289-293.
3. Tory, K., et al. 1989. Specific genetic change in tumors associated with von Hippel-Lindau disease. *J. Natl. Cancer Inst.* 81: 1097-1101.
4. Garrett, K.P., et al. 1994. Molecular cloning of an essential subunit of RNA polymerase II elongation factor SIII. *Proc. Natl. Acad. Sci. USA* 91: 5237-5241.
5. Krumm, A., et al. 1995. Tumor suppression and transcription elongation: the dire consequences of changing partners. *Science* 269: 1400-1401.
6. Aso, T., et al. 1995. Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II. *Science* 269: 1439-1443.
7. Duan, D.R., et al. 1995. Inhibition of transcription elongation by the VHL tumor suppressor protein. *Science* 269: 1402-1406.
8. Gross, D.J., et al. 1996. Familial pheochromocytoma associated with a novel mutation in the von Hippel-Lindau gene. *J. Clin. Endocrin. Metab.* 81: 147-149.
9. Waber, P.G., et al. 1996. Frequent allelic loss at chromosome arm 3p is distinct from genetic alterations of the von Hippel-Lindau tumor suppressor gene in head and neck cancer. *Oncogene* 12: 365-369.

## CHROMOSOMAL LOCATION

Genetic locus: VHL (human) mapping to 3p25.3.

## SOURCE

VHL (C-13) is an affinity purified goat polyclonal antibody raised against a peptide mapping at the C-terminus of VHL of human origin.

## STORAGE

Store at 4° C, **\*\*DO NOT FREEZE\*\***. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-100232 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

## APPLICATIONS

VHL (C-13) is recommended for detection of VHL of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for VHL siRNA (h): sc-36816, VHL shRNA Plasmid (h): sc-36816-SH and VHL shRNA (h) Lentiviral Particles: sc-36816-V.

Molecular Weight of VHL isoforms: 18/24 kDa.

Positive Controls: Hep G2 cell lysate: sc-2227.

## RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.

## PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) or our catalog for detailed protocols and support products.


 MONOS  
Satisfaction  
Guaranteed

Try **VHL (VHL40): sc-135657** or **VHL (G-7): sc-17780**, our highly recommended monoclonal alternatives to VHL (C-13). Also, for AC, HRP, FITC, PE, Alexa Fluor® 488 and Alexa Fluor® 647 conjugates, see **VHL (VHL40): sc-135657**.